Discovery of Broad Spectrum Dengue Virus Proteinase Inhibitors

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI079966-01
Agency Tracking Number: AI079966
Amount: $599,957.00
Phase: Phase I
Program: SBIR
Awards Year: 2008
Solicitation Year: 2008
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Small Business Information
DUNS: 620852769
HUBZone Owned: Y
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 () -
Business Contact
Phone: (808) 540-4711
Research Institution
DESCRIPTION (provided by applicant): Over half of the world population is at risk for infection by dengue virus, a mosquito borne member of the Flavivirus family that consists of four distinct serotypes. Approximately 50 to 100 million infections occur ann ually resulting in an estimated 500,000 cases of life threatening dengue hemorrhagic fever or dengue shock syndrome. Due to the increased incidence and spreading geographic distribution of dengue infection, it is considered to be an emerging disease and is identified by NIAID as a category A priority pathogen. Despite the significant disease burden associated with dengue infection there is presently no approved vaccine or antiviral drug. The goal of this project is to discover and develop antiviral drugs th at inhibit dengue virus infection by blocking the proteolytic activity of the dengue virus NS3 protein. The protease is a key enzyme in viral maturation and inhibition of flavivirus protease has been shown to dramatically reduce viral replication. Structur e based drug design will provide a rapid path to potent and virus specific protease inhibitors. We will virtually screen the active site with a chemical library. These targets will be examined by molecular modeling through a process of virtual drug screeni ng to find potential inhibitor compounds that will then be tested experimentally in vitro utilizing biochemical assays optimized during the course of the project. A cell based assay will also be used to confirm virus inhibition in a slightly more physiolog ical environment. Compounds that are active versus the Dengue NS3 proteinase of serotype 2 will also be tested versus the other 3 serotypes, in order to identify potential broad spectrum dengue antiviral therapeutics. At the conclusion of Phase I we intend to select at least one lead series with high potency to be optimized toward producing an effective broad spectrum dengue antiviral drug and possible other Flaviviruses during Phase II. PUBLIC HEALTH RELEVANCE: Dengue fever causes more illness and death th an any other arboviral disease and is spreading into new geographic areas, with 925,000 cases reported in 2006. No commercial prophylactic or therapeutic is available to treat the disease. Our strategy is to discover and optimize orally available antiviral drugs to prevent and treat Dengue virus infections, with potential broad spectrum activity versus all flaviviruses.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government